2020
DOI: 10.1016/j.jfo.2019.10.005
|View full text |Cite
|
Sign up to set email alerts
|

Clinical and therapeutic features of pediatric Vogt-Koyanagi-Harada disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0
1

Year Published

2021
2021
2023
2023

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 20 publications
0
1
0
1
Order By: Relevance
“…In a study by Reiff et al to assess the long term safety and efficacy of disease-modifying antirheumatic drugs (DMARDs) and biologics for treatment of paediatric and adolescent patients with pars planitis (PP), panuveitis (PU) and VKHD, they found 98% of patients required additional DMARDs and 73% required therapy with biologics.At the end of study 35% patients across all groups had significant visual loss or were blind.They concluded that as all three groups involve a high risk of permanent visual loss they should be managed by skilled rheumatologist early and aggressively [11]. In another study by Albaroudi et al on paediatic VKHD, they concluded that life expectancy justifies early initiation of immunesuppressive or even biological therapy to achieve better steroid sparing and most importantly preserve visual function [12]. Hence it is imperative that all suspicious cases should be investigated to rule out simmilar occurring inflammatory and noninflammtory diseases.…”
Section: Discussionmentioning
confidence: 99%
“…In a study by Reiff et al to assess the long term safety and efficacy of disease-modifying antirheumatic drugs (DMARDs) and biologics for treatment of paediatric and adolescent patients with pars planitis (PP), panuveitis (PU) and VKHD, they found 98% of patients required additional DMARDs and 73% required therapy with biologics.At the end of study 35% patients across all groups had significant visual loss or were blind.They concluded that as all three groups involve a high risk of permanent visual loss they should be managed by skilled rheumatologist early and aggressively [11]. In another study by Albaroudi et al on paediatic VKHD, they concluded that life expectancy justifies early initiation of immunesuppressive or even biological therapy to achieve better steroid sparing and most importantly preserve visual function [12]. Hence it is imperative that all suspicious cases should be investigated to rule out simmilar occurring inflammatory and noninflammtory diseases.…”
Section: Discussionmentioning
confidence: 99%
“…Хроничен, прогресиращ двустранен панувеит, който е свързан с ексудативни отлепвания на ретината и може да бъде придружен от менингеално дразнене, слухови нарушения и кожни промени. Той е рядък при деца, но засегнатите имат по-висока честота на очни усложнения като катаракта и глаукома и имат по-лоша прогноза относно зрението, особено когато се наблюдава панувеит в детска възраст, отколкото при възрастните [5,6]. and oligoarthritis and there is predominance of girls (2.3:1 -girls:boys).…”
Section: въведениеunclassified